Drug Profile
Dolutegravir - ViiV Healthcare
Alternative Names: '572; 1349572; Dolutegravir sodium; DTG; GSK-1349572; S-349572; S/GSK 1349572; Tivicay; Tivicay PDLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Shionogi-GlaxoSmithKline Pharmaceuticals
- Developer Bellvitge University Hospital; GSK; INSERM; National Institute of Allergy and Infectious Diseases; National Institutes of Health (USA); PENTA Foundation; Shionogi-GlaxoSmithKline Pharmaceuticals; University of Liverpool; Viatris; ViiV Healthcare
- Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Oxazines; Small molecules
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HIV-1 infections
- Phase III HIV infections
Most Recent Events
- 05 Oct 2022 Phase-I clinical trials in HIV-1 infections (In infants, In neonates, Prevention) in USA (PO) (NCT05406583)
- 05 Oct 2022 Phase-I clinical trials in HIV-1 infections (Prevention, In neonates, In infants) in USA (PO) (NCT05406583)
- 15 Aug 2022 GlaxoSmithKline and ViiV Healthcare completes a phase III Gemini 1 trial in HIV-1 infections (Combination therapy, Treatment-naive) in Argentina, Australia, Belgium, Canada, France, Germany, Italy, Mexico, Netherlands, Portugal, Romania, Russia, South Africa, Spain, South Korea, Taiwan, United Kingdom and USA (PO) (NCT02831673) (EudraCT2015-004418-95)